Daniëlle J. Vugts

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

Anna-Larissa N. Niemeijer, David Leung, Marc C. Huisman et al. · Nature Communications · 2018 · 483 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Géraldine Gebhart, Laetitia E. Lamberts, Zéna Wimana et al. · Annals of Oncology · 2015 · 348 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101)

Pieter J. Gaillard, Chantal C.M. Appeldoorn, Rick Dorland et al. · PLoS ONE · 2014 · 284 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Christian Klein, Inja Waldhauer, Valeria Nicolini et al. · OncoImmunology · 2017 · 283 citations · Full text

Life Sciences, Immunology, Oncology +17

Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET

Daniëlle J. Vugts, Chris Klaver, Claudia Sewing et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2016 · 148 citations · Full text

Medicine, Medicinal Chemistry, Nuclear Medicine +17